Note 10. Share-based Compensation:

During the quarter ended September 30, 2024 and 2023, the Company granted 0.8 million and 0.8 million stock options at weighted average grant prices of $74.85 and $84.34 and weighted average fair values of $25.32 and $28.58, respectively. During the quarter ended September 30, 2024 and 2023, the Company granted 468,866 and 268,961 restricted stock units at a weighted average fair value of $74.92 and $84.44, respectively. During the quarter ended September 30, 2024 and 2023, the Company did not grant restricted common stock shares.

Stock options for 648,293 and 1,027,777 shares of common stock with total intrinsic values of $23.5 million and $54.3 million were exercised during the quarter ended September 30, 2024 and 2023, respectively.

Stock-based compensation expense, inclusive of payroll taxes, of $10.3 million and $11.1 million was included in selling, general and administrative expenses for the quarter ended September 30, 2024 and 2023 respectively. Additionally, the Company recognized $0.3 million of stock-based compensation costs in cost of goods sold during the quarter ended September 30, 2024 compared to $0.2 million in the comparative prior year period. As of September 30, 2024, there was $72.5 million of unrecognized compensation cost related to non-vested stock options, non-vested restricted stock units and non-vested restricted stock. The weighted average period over which the compensation cost is expected to be recognized is 2.2 years.